H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $85 from $75 and keeps a Buy rating on the shares. The company reported “strong” topline data from the ongoing Phase 3 ORIGIN study evaluating atacicept for the treatment of immunoglobulin A nephropathy, the analyst tells investors in a research note. The firm says the drug demonstrated a 46% reduction from baseline in urine protein creatinine ratio, resulting in a statistically significant 42% reduction compared to placebo at week 36. The results not only confirm atacicept’s therapeutic potential for IgAN treatment but also provide convincing evidence to support its best-in-class potential, contends H.C. Wainwright. It views the data as a “home run.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics Announces Positive Phase 3 Trial Results
- Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept
- 3 Best Stocks to Buy Now, 5/29/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 5/26/2025, According to Top Analysts
- Buy Rating for Vera Therapeutics Driven by Promising Phase III Results and Market Potential